lemms personal page - To The Moon

lemms

lemms

No personal profile

12Follow

5Followers

0Topic

0Badge

2021-08-10

Wow... Visa is going to be affected by this for sure.

Sorry, the original content has been removed

2021-08-12

I like chewy, but hesitant about Roku. I had their box previously, but didn't find it useful. A cheap android box from huaqiangbei is more than enough to replace Roku.

Sorry, the original content has been removed

2021-08-31

Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.

AC Immune shares surged more than 70% in early trading

2021-08-12

If there is "if only...", then there will not be beggars...

Sorry, the original content has been removed

06-21

I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.

2021-03-08

Can we buy stocks that grow pot? I tried, but got rejected.

Canada eyes tighter rules for grow-your-own pot producers

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3562228884568927","uuid":"3562228884568927","gmtCreate":1599135270304,"gmtModify":1615256527965,"name":"lemms","pinyin":"lemms","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":12,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"60.49%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.23","exceedPercentage":"60.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":448451925868560,"gmtCreate":1750511770173,"gmtModify":1750511773601,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.","listText":"I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.","text":"I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/448451925868560","isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818599234,"gmtCreate":1630417869628,"gmtModify":1676530298114,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","listText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","text":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818599234","repostId":"1174676883","repostType":4,"repost":{"id":"1174676883","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://ttm.financial/m/news/1174676883?lang=en_US&edition=fundamental","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-31 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1,"symbols_score_info":{"ACIU":0.9}},"isVote":1,"tweetType":1,"viewCount":2851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894068067,"gmtCreate":1628778283459,"gmtModify":1676529852631,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","listText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","text":"I like chewy, but hesitant about Roku. I had their box previously, but didn't find it useful. A cheap android box from huaqiangbei is more than enough to replace Roku.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894068067","repostId":"2158709252","repostType":4,"isVote":1,"tweetType":1,"viewCount":2619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895994847,"gmtCreate":1628700074689,"gmtModify":1676529827020,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"If there is \"if only...\", then there will not be beggars...&nbsp;","listText":"If there is \"if only...\", then there will not be beggars...&nbsp;","text":"If there is \"if only...\", then there will not be beggars...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895994847","repostId":"2158474560","repostType":4,"isVote":1,"tweetType":1,"viewCount":1768,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896592259,"gmtCreate":1628591122471,"gmtModify":1703508682416,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"Wow... Visa is going to be affected by this for sure.&nbsp;","listText":"Wow... Visa is going to be affected by this for sure.&nbsp;","text":"Wow... Visa is going to be affected by this for sure.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/896592259","repostId":"2158761427","repostType":4,"isVote":1,"tweetType":1,"viewCount":3327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329807435,"gmtCreate":1615218260227,"gmtModify":1704779784726,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3562228884568927","authorIdStr":"3562228884568927"},"themes":[],"htmlText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","listText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","text":"Can we buy stocks that grow pot? I tried, but got rejected.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329807435","repostId":"1148943101","repostType":4,"repost":{"id":"1148943101","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615206066,"share":"https://ttm.financial/m/news/1148943101?lang=en_US&edition=fundamental","pubTime":"2021-03-08 20:21","market":"us","language":"en","title":"Canada eyes tighter rules for grow-your-own pot producers","url":"https://stock-news.laohu8.com/highlight/detail?id=1148943101","media":"Reuters","summary":"Canada’s health regulator will launch a public consultation program on Monday in its draft guidance ","content":"<p>Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.</p>\n<p>In the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.</p>\n<p>The move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.</p>\n<p>“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.</p>\n<p>The draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.</p>\n<p>Health Canada could not be immediately reached for comment.</p>\n<p>Canada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.</p>\n<p>Households spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.</p>\n<p>In January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.</p>\n<p>Under the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.</p>\n<p>Health Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.</p>\n<p>Personal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.</p>\n<p>Health Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.</p>\n<p>After the end of the two-month period, the regulator plans to finalize the guidance and make it public.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Canada eyes tighter rules for grow-your-own pot producers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanada eyes tighter rules for grow-your-own pot producers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-08 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.</p>\n<p>In the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.</p>\n<p>The move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.</p>\n<p>“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.</p>\n<p>The draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.</p>\n<p>Health Canada could not be immediately reached for comment.</p>\n<p>Canada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.</p>\n<p>Households spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.</p>\n<p>In January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.</p>\n<p>Under the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.</p>\n<p>Health Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.</p>\n<p>Personal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.</p>\n<p>Health Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.</p>\n<p>After the end of the two-month period, the regulator plans to finalize the guidance and make it public.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","CRON":"Cronos Group Inc.","APHA":"Aphria Inc.","MJ":"Amplify Alternative Harvest ETF","ACB":"奥罗拉大麻公司","CGC":"Canopy Growth Corporation","SNDL":"SNDL Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148943101","content_text":"Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.\nIn the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.\nThe move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.\n“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.\nThe draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.\nHealth Canada could not be immediately reached for comment.\nCanada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.\nHouseholds spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.\nIn January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.\nUnder the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.\nHealth Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.\nPersonal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.\nHealth Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.\nAfter the end of the two-month period, the regulator plans to finalize the guidance and make it public.","news_type":1,"symbols_score_info":{"ACB":0.9,"CGC":0.9,"SNDL":0.9,"TLRY":0.9,"CRON":0.9,"APHA":0.9,"MJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":896592259,"gmtCreate":1628591122471,"gmtModify":1703508682416,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"Wow... Visa is going to be affected by this for sure.&nbsp;","listText":"Wow... Visa is going to be affected by this for sure.&nbsp;","text":"Wow... Visa is going to be affected by this for sure.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/896592259","repostId":"2158761427","repostType":4,"isVote":1,"tweetType":1,"viewCount":3327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894068067,"gmtCreate":1628778283459,"gmtModify":1676529852631,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","listText":"I like chewy, but hesitant about Roku.&nbsp;I had their box previously, but didn't find it&nbsp;useful. A cheap android box from huaqiangbei is more than enough to replace Roku.&nbsp;","text":"I like chewy, but hesitant about Roku. I had their box previously, but didn't find it useful. A cheap android box from huaqiangbei is more than enough to replace Roku.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894068067","repostId":"2158709252","repostType":4,"isVote":1,"tweetType":1,"viewCount":2619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818599234,"gmtCreate":1630417869628,"gmtModify":1676530298114,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","listText":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;","text":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818599234","repostId":"1174676883","repostType":4,"repost":{"id":"1174676883","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://ttm.financial/m/news/1174676883?lang=en_US&edition=fundamental","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-31 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1,"symbols_score_info":{"ACIU":0.9}},"isVote":1,"tweetType":1,"viewCount":2851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895994847,"gmtCreate":1628700074689,"gmtModify":1676529827020,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"If there is \"if only...\", then there will not be beggars...&nbsp;","listText":"If there is \"if only...\", then there will not be beggars...&nbsp;","text":"If there is \"if only...\", then there will not be beggars...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895994847","repostId":"2158474560","repostType":4,"isVote":1,"tweetType":1,"viewCount":1768,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":448451925868560,"gmtCreate":1750511770173,"gmtModify":1750511773601,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.","listText":"I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.","text":"I’ve been taking autonomous robotaxi in China since last year. It is still in trial stage, so the coverage area is limited. The ride was smooth, I felt safe, the screen shows what the car ‘sees’, and it was easy to book and pay for the ride. I see the looming end for taxi drivers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/448451925868560","isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329807435,"gmtCreate":1615218260227,"gmtModify":1704779784726,"author":{"id":"3562228884568927","authorId":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3562228884568927","idStr":"3562228884568927"},"themes":[],"htmlText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","listText":"Can we buy stocks that grow pot? I tried, but got rejected.&nbsp;","text":"Can we buy stocks that grow pot? I tried, but got rejected.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329807435","repostId":"1148943101","repostType":4,"repost":{"id":"1148943101","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615206066,"share":"https://ttm.financial/m/news/1148943101?lang=en_US&edition=fundamental","pubTime":"2021-03-08 20:21","market":"us","language":"en","title":"Canada eyes tighter rules for grow-your-own pot producers","url":"https://stock-news.laohu8.com/highlight/detail?id=1148943101","media":"Reuters","summary":"Canada’s health regulator will launch a public consultation program on Monday in its draft guidance ","content":"<p>Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.</p>\n<p>In the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.</p>\n<p>The move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.</p>\n<p>“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.</p>\n<p>The draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.</p>\n<p>Health Canada could not be immediately reached for comment.</p>\n<p>Canada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.</p>\n<p>Households spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.</p>\n<p>In January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.</p>\n<p>Under the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.</p>\n<p>Health Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.</p>\n<p>Personal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.</p>\n<p>Health Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.</p>\n<p>After the end of the two-month period, the regulator plans to finalize the guidance and make it public.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Canada eyes tighter rules for grow-your-own pot producers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanada eyes tighter rules for grow-your-own pot producers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-08 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.</p>\n<p>In the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.</p>\n<p>The move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.</p>\n<p>“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.</p>\n<p>The draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.</p>\n<p>Health Canada could not be immediately reached for comment.</p>\n<p>Canada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.</p>\n<p>Households spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.</p>\n<p>In January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.</p>\n<p>Under the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.</p>\n<p>Health Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.</p>\n<p>Personal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.</p>\n<p>Health Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.</p>\n<p>After the end of the two-month period, the regulator plans to finalize the guidance and make it public.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc.","CRON":"Cronos Group Inc.","APHA":"Aphria Inc.","MJ":"Amplify Alternative Harvest ETF","ACB":"奥罗拉大麻公司","CGC":"Canopy Growth Corporation","SNDL":"SNDL Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148943101","content_text":"Canada’s health regulator will launch a public consultation program on Monday in its draft guidance for individuals growing medical cannabis at home, hoping to clamp down on people selling weed on the black market.\nIn the draft document sent to some industry figures and seen by Reuters ahead of publication, Health Canada highlights recent police raids and arrests at production sites where people were using licenses to “cover and support large-scale illegal production and sale”.\nThe move also comes as Health Canada tries to set right a relatively unstable official market, where illegal sales are one factor undermining the business plans of the dozens of producers and distributors set up over the past five years.\n“Abuse of the medical purposes framework undermines the integrity of the system that many patients and health care practitioners rely on to access cannabis to address their medical needs,” Health Canada said in the document.\nThe draft guidance for the first time sets out factors that the regulator may consider in refusing or revoking a registration for “personal production”. Factors include authorization of unjustified amounts and “criminal activity and/or diversion of cannabis”.\nHealth Canada could not be immediately reached for comment.\nCanada in 2018 was the first major country to legalize cannabis but its programs have since run into a myriad of troubles.\nHouseholds spent more than C$3.1 billion buying non-medical pot from illicit channels last year versus C$2.9 billion of legal purchases, according to Statistics Canada data.\nIn January, Ontario Provincial Police seized over 180,000 cannabis plants and numerous vehicles and firearms by raiding illegal cultivation facilities, many of which exploit Health Canada’s personal medical weed cultivation licenses.\nUnder the rules, people using cannabis for medical purposes must get a daily amount authorized by medical care practitioners - doctors, nurses and social workers - to either be bought from official retailers or grown personally.\nHealth Canada said in December it was seeing a surge in the amount of pot personal cultivators were being authorized to grow.\nPersonal cultivators are allowed to grow as much as 36 grams per day on average, compared with just 2 grams authorized for daily purchase from retailers.\nHealth Canada will invite “interested stakeholders” to comment in the public consultation, expected to run for 60 days through May 7, with the aim of improving the programs’ operation and judging what factors it should consider when assessing risks to public health, the guidance said.\nAfter the end of the two-month period, the regulator plans to finalize the guidance and make it public.","news_type":1,"symbols_score_info":{"ACB":0.9,"CGC":0.9,"SNDL":0.9,"TLRY":0.9,"CRON":0.9,"APHA":0.9,"MJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}